Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of FK506E (MR4) in Patients Undergoing Primary Kidney Transplantation [Phase 3]

View source ↗

Summary

Phase 3 study evaluating the safety and efficacy of FK506E (MR4) in patients undergoing primary kidney transplantation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• FK506E (MR4)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Kidney Transplantation | Phase 3 | Status: COMPLETED